Dr. Penson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Yaw 9
Hematology/Oncology
Boston, MA 02114Phone+1 617-724-5951Fax+1 617-724-6898
Summary
- Dr. Richard Penson is a medical oncologist in Boston, MA at the Massachusetts General Hospital. He received his medical degree from Bart's and has been in practice 30 years. He is a key opinion leader in gynecologic cancer.
Education & Training
Barts and The London SOM & DentClass of 1987, MBBS, MRCP MD
Certifications & Licensure
MA State Medical License 2004 - 2025
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Start of enrollment: 2005 Jun 01
- GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer Start of enrollment: 2004 Dec 01
- Neuropathic Pain in Patients With Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.Katherine Elizabeth Francis, Sandy Simon, Val Gebski, Florence Joly, Jonathan A Ledermann
Gynecologic Oncology. 2025-01-01 - Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.Giovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, David Cibula, Charles A Leath 3rd
Journal of Clinical Oncology. 2024-12-12 - 1 citationsA phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receivi...Joyce F Liu, Niya Xiong, Robert M Wenham, Andrea Wahner-Hendrickson, Deborah K Armstrong
Gynecologic Oncology. 2024-08-01
Lectures
- Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 tr...2019 ASCO Annual Meeting - 6/1/2019
- Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GO...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Clinical features, diagnosis, staging, and treatment of uterine carcinosarcomaPenson RT, Powell MA
http://www.uptodate.com/contents/clinical-features-diagnosis-staging-and-treatment-of-uterine-carcin
UpToDate, Wolters Kluwer Health - 2013-04-01 - Cisplatin nephrotoxicityPenson RT, Safar AM, Portilla D, Shannon ML
http://www.uptodate.com/contents/cisplatin-nephrotoxicity
UpToDate, Wolters Kluwer Health - 2012-08-13
Press Mentions
What’s Next for Immunotherapy in Ovarian Cancer After “Disappointing” VB-111 Results?August 8th, 2022- Olaparib Did Not Improve PFS2, OS in SOLO3 TrialMarch 19th, 2022
The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019July 3rd, 2020- Join now to see all
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
